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Abstract
Acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy. Genome-wide association studies have
shown variation at 14q11.2 inﬂuences ALL risk. We sought to decipher causal variant(s) at 14q11.2 and the mechanism of
tumorigenesis. We show rs2239630 G>A resides in the promoter of the CCAT enhancer-binding protein epsilon (CEBPE)
gene. The rs2239630-A risk allele is associated with increased promotor activity and CEBPE expression. Depletion of
CEBPE in ALL cells reduces cell growth, correspondingly CEBPE binds to the promoters of electron transport and energy
generation genes. RNA-seq in CEBPE depleted cells demonstrates CEBPE regulates the expression of genes involved in B-
cell development (IL7R), apoptosis (BCL2), and methotrexate resistance (RASS4L). CEBPE regulated genes signiﬁcantly
overlapped in CEBPE depleted cells, ALL blasts and IGH-CEBPE translocated ALL. This suggests CEBPE regulates a
similar set of genes in each, consistent with a common biological mechanism of leukemogenesis for rs2239630 associated
and CEBPE translocated ALL. Finally, we map IGH-CEBPE translocation breakpoints in two cases, implicating RAG
recombinase activity in their formation.
Introduction
Acute lymphoblastic leukemia (ALL) is the most common
pediatric cancer in western countries. While the aetiology of
ALL is poorly understood evidence implicates initiating
transforming events occuring in utero [1–3], with secondary
events required for transition to malignancy [4].
Our understanding of ALL susceptibility has been trans-
formed by genome-wide association studies (GWAS) [5–8].
GWAS have identiﬁed 11 loci associated with ALL, including
the 14q11.2 risk locus, which has been replicated in multiple
independent series [9, 10]. ALL risk loci often map in the
vicinity of B-cell development genes, including IKZF1,
GATA3, ARID5B and at 14q11.2 mapping to CCAT enhancer-
binding protein epsilon (CEBPE) [6], suggesting a central role
for dysregulated B-cell development in leukemogenesis. Cor-
respondingly, crucial B-cell development transcription factors
IKZF1, PAX5, and EBF1 are also the targets of frequent
somatic mutation [11, 12], highlighting that GWAS signals
and somatic mutations may impact upon the same genes.
Around 60% of BCP-ALL is characterised by trans-
locations, most common of which, t(12:21) produces the
chimeric, ETV6-RUNX1, transcription factor. Three
percent of BCP-ALL features a translocation at the
immunoglobulin heavy chain (IGH) locus that often
involves a CEBP family member. These juxtapose IGH
with the coding region of CEBP, increasing CEBP
expression [13], raising the possibility that the 14q11.2
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GWAS association is also mediated through increased
CEBPE expression.
We sought to identify the causal polymorphism(s) for the
14q11.2 association. Our data are compatible with
rs2239630 in the promoter of CEBPE driving the associa-
tion and increasing CEBPE expression.
Material and methods
Ethics
Samples and clinicopathological information were collected
with ethical board approval. ALL blast RNA sequencing
and genotyping sample collection was approved by the
Lund University, nos 2011/289 and 2017/796. Informed
consent was granted from all participants.
GWAS
UK GWAS and German GWAS have been previously
reported [6, 7]. Brieﬂy, the UK GWAS comprised 824
cases, genotyped using Illumina Human 317 K arrays;
WTCC2 controls were of 2699 of 1958 British Birth Cohort
and 2501 from the UK Blood Service. German GWAS
comprised 834 cases, genotyped using Illumina Human
OmniExpress-12v1.0 arrays. Controls comprised 2024
individuals from the Heinz Nixdorf Recall study [14].
GWAS QC has been described previously [7]. Untyped
genotypes were imputed using IMPUTE2 v2.3 [15] with
combined UK10K (ALSPAC and TwinsUK) [16] and 1000
Genomes Project (phase III) [17] references. Poorly impu-
ted SNPs (INFO score <0.8) were excluded. Association
between SNP and ALL was performed using
SNPTESTv2.5 [18]. Meta-analysis was undertaken using
META v1 [18].
Hi-C data analysis
Hi-C data in Supplementary Fig.1 derived from GM12878
(MboI plus replicate) was obtained from (https://www.
aidenlab.org/juicebox/) [19]. Data were viewed using
balanced Knight-Ruiz normalisation at 5 kb resolution. Hi-
C data in Supplementary Fig.7 (GM12878 and human
embryonic stem cells) were from (http://yunliweb.its.unc.
edu/HUGIn/; GSE87112).
Cell lines and lentiviral transduction
REH, NALM6, and SEM B-ALL, Jurkat T-ALL cell lines
were obtained from DMSZ (Braunschweig Germany).
GM12815 and GM12760 were obtained from the Coriell
Institute (Camden NJ, US). Cell lines were maintained at
37 °C, with 5% CO2 in RPMI with 10% FBS and Gluta-
MAX (Thermo Fisher Scientiﬁc). Doxycyclin inducible
CEBPE shRNA knockdown, CEBPE and ZNF148 over-
expressing cell lines were generated by lentiviral transduc-
tion using CEBPE (V3THS_150517(A13), V3THS_404312
(G3)), Empty, Non-targeting pTRIPZ or pCW57.1 vectors
(GE Life Sciences or from David Root Addgene plasmid #
41393) into REH. Lentiviral particles were produced in
HEK239T cells as described [20, 21]. Transduced REH
cells were selected with 750 ng/ml puromycin for 1 week.
Polyclonal populations were used for all assays. Cells were
tested for mycoplasma using Promokine PCR Mycoplasma
Test Kit I/C, no positive results were obtained. Cell identity
was conﬁrmed using Promega PowerPlex 16 microsatellite
testing kit.
Plasmid construction and luciferase assays
The CEBPE promoter containing rs2239630, rs2239632
and rs2239633 and ZNF148 coding sequence cloned in
pGL3 Promoter Vector (Promega) or pCW57.1 doxycycline
inducible vectors, respectively. For luciferase assays, cells
were electroporated and promoter activity was assayed
using a Dual-Luciferase assay (Promega). Full methods are
described in Supplementary material.
Genotyping and sequencing
PCR for sequencing was carried out using Thermoprime
DNA polymerase (Thermo Fisher Scientiﬁc). BigDye
v3.1 sequencing reactions were analysed on an ABI7900HT
(Applied Biosystems) (Primers in Supplementary Table 1).
The concordance between imputation of rs2239630 and
133 sequenced genotypes was 96% (R2= 0.90).
ChIP-seq data mining, Blueprint, and Roadmap
chromatin state dynamics
B-cell epigenetic proﬁles were obtained from Roadmap [22]
and Blueprint [23] projects and ENCODE. Chromatin state
dynamics (ChomHMM) for E031 is from (http://egg2.
wustl.edu/roadmap/data/byFileType/chromhmm Segmenta-
tions/ChmmModels/coreMarks/jointModel/ﬁnal/) and for
GM12878 from (http://hgdownload.cse.ucsc.edu/goldenPa
th/hg19/encodeDCC/wgEncodeBroadHmm/ wgEncodeB-
roadHmmGm12878HMM.bed.gz). DNAse hypersensitivity
data from the ALL blast pz294 (European Genome-
phenome Archive EGAD00001002499) is from (ftp://ftp.
ebi.ac.uk/pub/databases/blueprint/data/homo_sapiens/GRC
h38/bone_marrow/pz_294/Acute_Lymphocytic_Leukemia_
CTR/DNase-Hypersensitivity/NCMLS/) and for GM12
878 from (http://hgdownload.cse.ucsc.edu/goldenPath/
hg19/encodeDCC/wgEncodeUwDnase/ wgEncodeUwDna
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seGm12878HotspotsRep2.broadPeak.gz). Proteins binding
SNP rs2239630 extracted from Encode (http://hgdownload.
cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeReg
TfbsClustered/wgEncodeRegTfbsClusteredV3) and ChIP
Atlas (http://chip-atlas.org) ChIP-seq data. REH H3K
27ac ChIP-Seq data were obtained from GSE84052
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GS
E84052).
ChIP
Cells were ﬁxed in 1% formaldehyde in media for 10min at
RT with agitation and quenched in 125mM glycine. ChIP
was performed using the Active Motif ChIP-IT Express kit
(Active Motif), except after mircococcal nuclease DNA
digestion, cells were sonicated in a Biorupter (Diagenode) for
10 min on high 30 s ON/OFF at 4 °C. A total of 25 µg of
chromatin was incubated with 2 µg of either anti-YY1
(Abcam ab12132), ELF1 (Santa Cruz sc-133096), MAX
(Abcam ab53570), E2A (Santa Cruz sc133075), ZNF148
(Atlas Antibodies HPA001656), 0.5 µg of SPI1 (Life Tech-
nologies A13971) or an equal amount of control antibody,
mouse IgG2b (Thermo Fisher Scientiﬁc MA5-14447) or
rabbit IgG (AbCam ab37415) and incubated at 4 °C O/N with
rotation. Target quantities were interpolated and normalised to
input DNA (primers in Supplementary Table 2). rs2239630
allele-speciﬁc q-RT PCR primers demonstrated a 300-fold
allele preference.
ChIP-sequencing
ChIP-Seq sample preparation was performed as above, using
2 µg anti-CEBPE (Atlas Antibodies HPA002928), except: (1)
After ﬁnal ChIP wash, DNA was eluted in 100 µl of 1% SDS
and 100mM NaHCO3 for 15min at RT with rotation. (2)
After the addition of 4 µl of 5M NaCl and protinase K
digestion as per guidelines, duplicate reactions were pooled
and puriﬁed using QIAquick PCR Puriﬁcation columns
(Qiagen). A total of 10 ng of ChIP’d and input DNA was used
as material for Illumina NGS preparation using NEBNext
ChIP-Seq Library preparation kit (New England Biolabs) and
sequenced on a MiSeq using 150 bp Kit v3 (Illumina). Raw
FASTQ ChIP-seq reads (CEBPE and H3K27ac) were map-
ped to human reference genome (human_g1k_v37) using
Stampy v1.0.28, for H3K27ac data common (>1% frequency)
SNPs (dbSNP build 150) were edited to ‘N’. BAM ﬁles were
ﬁltered to remove sequences with <MAPQ30 score. Peaks
were called using MACS2 2.1.1 [24] against input DNA.
Putative CEBPE-regulated genes are listed in Supplementary
Table 7 (deﬁned as those with an Ensembl 90 TSS within 1
kb of a peak). CEBPE ChIP motif discovery was performed
using HOMER 4.9.1 [25].
siRNA transfection and reverse transcription
A total of 4 × 106 REH were electroporated with 200 nM of
siRNA (Euroﬁns Genomics) (sequences in Supplementary
Table 3) as described above and incubated for 24 h before
lysis. RNA was prepared using the Qiagen RNAeasy kit. A
total of 1–2 µg of RNA was reverse transcribed using
MMLV (Promega) and 5 µM dT15.
qRT-PCR
qRT-PCR was performed using SYBR Green (Thermo Fisher
Scientiﬁc). Samples were analysed undiluted for ChIP or 1/
100 for cDNA. Biological replicates contained three technical
replicates. PCR-quantitation, by standard curve method.
Fivefold serial dilutions of DNA or cDNA were used to
control for differential primer efﬁciency. For siRNA assays
target gene expression was normalised to the geometric
average of PPIA, TBP or PPIA, TUBβ as indicated.
Electrophoretic mobility shift assay
EMSAs were performed as described in ref. [26] using
rs2239630 allele-speciﬁc probes (5′-AGGCTGGTGCT
TCGCCCCTC[A/G]CCCTGGGCCTGAGGCTCTGC-3′).
Supershift assays were performed using anti-ZNF148 (Atlas
Antibodies HPA001656) or IgG isotype control (AbCam
ab37415). Full methods are described in Supplementary
materials.
Cell growth assay
Cell viability was quantiﬁed using a ﬁnal concentration of
0.5 mg/ml MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide, Sigma) at 37 °C for 2 h and reac-
tions stopped with an equal volume of 10% SDS with
0.01% of 37% HCl. Plates were incubated for 24 h in the
dark and absorbance read at 562 nm.
Flow cytometry
For cell cycle analysis, around 106 cells were suspended in
500 µl of −20 °C 70% v/v ethanol and ﬁxed at −20 °C O/N,
before resuspension in 500 µl ml of 1× propidium iodide
(20 μg/ml (Sigma), 50 μg/ml RNase (Sigma) in PBS) for 2 h
at RT. Data analysis was performed in FlowJo software
(Tree Star Inc.) using the Watson Pragmatic algorithm. For
annexin-V apoptosis assays ~100,000 cells were stained in
100 µl of buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM
CaCl2) with 5 µl of APC annexin-V (BD Pharmingen
550474) and 5 µl 20 µg/ml DAPI (4′,6-diamidino-2-pheny-
lindole). Cells were stained for 15 min in the dark before the
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Fig. 1 Regional association plot for 14q11.2. a and b show SNPs (red
circles) plotted by GWAS P-values (−log10, y-axis) and location (x-
axis, GRCh37/hg19). Recombination rate (cM/Mb) light blue line (y-
axis). SNP colour denotes linkage disequilibrium with the lead SNP,
(r2= 0, white, r2= 1.0, dark red). a Association plot annotated with
genes from Gencode v27. Multicolour bar shows B-cell chromatin
states from ChomHMM. b Association plot of SNPs within 1 kb of the
lead SNP. Blue lines denote transcription factor ChIP-Seq peaks.
Black bar, B-cell DNAse hypersensitivity peak
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addition of 400 µl of buffer, all analyses were on a LSRII
cytometer (Becton Dickinson).
Cell line RNA-sequencing
shRNA expression was induced in REH cells with 1 μg/ml
doxycycline (Sigma). Cells were lysed after 144 h and
RNA prepared using Qiagen RNAeasy. CEBPE knock-
down was veriﬁed by qRT-PCR. RNA integrity was
assessed using a Tape Station 2200 (Agilent). Three
biological replicates were processed each with two con-
trols, (empty, non-targeting shRNA) and two CEBPE
shRNAs (A13 and G3). Libraries were prepared using
NEBNext Ultra II Directional RNA Library Prep Kit and
sequenced on an Illuimna HiSeq 2500 using 2 × 101
version 4 paired end chemistry. RNA QC metrics are
provided in Supplementary Table 4. FASTQs were ﬁl-
tered to remove adapter contamination using Trimmo-
matic v0.32 [27] and aligned to the human reference
genome (human_g1k_v37) and transcript reference
(GRCh37.87) using STAR v2.5.1 [28]. Gene and tran-
script abundance were quantiﬁed using RSEMv1.3.0 [29].
Non-coding genes and those with <10 mapped reads in all
samples were excluded. Raw gene counts were analysed
using EdgeR [30] and DeSeq2 [31].
ALL blast RNA-sequencing
IGH-CEBPE translocation BCP-ALL expression data ori-
ginated from two cohorts. A total of 195 diagnostic cases
[32] from Lund University analysed using TCGA RNA
sequencing version 2 pipeline quantiﬁed by RSEM value
and 231 diagnostic [33] cases from the National University
of Singapore analysed as per ‘Alignment and Bioinformatic
Processing of RNA-Sequencing.’
Gene expression in 2 IGH-CEBPE cases was quantiﬁed
by Z-score calculated from RSEM TPM (transcripts per 106)
based on the mean per gene expression of all non-IGH-
CEBPE translocated cases in each cohort.
RNA-Seq from 117 diagnostic BCP-ALL cases from
TARGET was downloaded from (ftp://caftpd.nci.nih.gov/
pub/OCG-DCC/TARGET/ALL/mRNA-Seq/Phase2/L3/
expression/BCCA/). Gene expression data were converted
to TPM before Spearman correlation analysis in R3.4.2
Blasts were unselected based on molecular subtype.
SNP arrays
A total of 150 BCP-ALL cases from the Lund cohort with
expression data were genotyped using either Illumina Human
1M-duo Inﬁnium BeadChip, HumanOmni1-Quad BeadChip
or IlluminaOmni5M BeadChips as previously described [34,
35], and untyped SNPs imputed from the UK10K and 1000
Genomes project reference panels using the Sanger Imputa-
tion Server (https://imputation.sanger.ac.uk/).
Data availability
Raw fastq data of RNA-seq from CEBPE-depleted REH
cells and CEBPE ChIP-seq from REH has been deposited in
the European Genome Phenome archive (https://www.ebi.
ac.uk/ega/home EGAS00001002877).
Fig. 2 rs2239630 inﬂuences CEBPE expression and promoter activity.
a Box (showing interquartile range and median) and whiskers
(min–max) plot of CEBPE expression (y-axis quantiﬁed by RSEM) by
rs2239630 genotype (x-axis) in B-cell ALL blasts (n= 44).
Kruskal–Wallis P-value computed against all genotypes. b CEBPE
promoter reporter assay for alleles of rs2239630. y-axis shows nor-
malised luciferase activity relative to empty vector. Data points, mean
of three biological replicates ± SEM (Student’s T-test). Figures pro-
duced in GraphPad Prism 7
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Results
Epigenomic proﬁling of the 14q11.2 locus
We reviewed a meta-analysis of UK and German GWASs
[8], ﬁne-mapping the 14q11.2 risk locus by imputation.
The strongest association was the imputed SNP
rs2239630 (P= 1.66 × 10−19, odds ratio= 1.45, Phet=
0.38, Fig.1a and Supplementary Table 5). We veriﬁed
imputation of rs2230630 by sequencing 133 cases. Con-
ditional analysis provided no evidence for an additional
independent association. Referencing SNPdb.v150 con-
ﬁrmed imputation captured 100% of variants (minor allele
frequency [MAF] > 0.01) within the linkage dis-
equilibrium (LD) block containing rs2239630 (pairwise
r2 ≥ 0.4).
We examined the regulatory potential of SNPs in LD
with rs2239630 using chromatin state modelling [36] in
primary B-cells, showing lead SNPs reside in an active
promoter. Additionally, a region of B-cell DNAse hyper-
sensitivity overlaps rs2239630 (Fig. 1a, b). Encode [37] and
Chip Atlas (http://chip-atlas.org/) ChIP-Seq data also
revealed binding sites for MAX, YY1, ELF1, SPI1, and
TCF3 overlapping rs2239630 (Fig.1b).
rs2239630 inﬂuences CEBPE expression and
promoter activity
We examined whether 14q11.2 risk SNPs inﬂuence CEBPE
expression by performing expression quantitative trait loci
analysis (eQTL) in ALL blast cells. Restricting our analysis
to chr14 disomic blasts (n= 44), the rs2239630-A risk
allele was associated with 1.8-fold increased CEBPE
expression (Kruskal–Wallis P= 0.046, Fig. 2a). A similar
association was seen in MuTHER (P= 0.017) [38] and
Blood (P= 4 × 10−4) [39] lymphoblastoid cell line datasets.
To exclude the potential of a looping cis-regulatory inter-
action we examined GM12878 Hi-C data [19]. This
revealed an interaction between the 14q11.2 locus and the
promoter of SLC7A8 (Supplementary Fig.1A), however no
signiﬁcant association between rs2239630 genotype and
SLC7A8 expression was seen in either ALL blasts (P=
0.14, Supplementary Fig.1B), MuTHER (P= 0.31) or
blood (P > 0.05) eQTLs datasets.
Fig. 3 rs2239630 alleles
differentially bind SPI1, MAX.
a ChIP q-PCR of MAX and
SPI1 enriched chromatin in REH
cells. x-axis lists genomic loci of
PCR primers used to amplify
antibody speciﬁc (MAX or
SPI1, black bars) or negative
control (IgG, grey bars) ChIP
samples. Raw signal normalised
to input DNA (left y-axis). Right
y-axis shows fold enriched
(hashed bars) of antibody
speciﬁc % input vs IgG control.
b Allele-speciﬁc ChIP q-PCR
for MAX and SPI1 in REH
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We assessed whether risk SNP genotype inﬂuences
CEBPE promoter activity, performing luciferase reporter
assays. REH cells transfected with constructs containing the
rs2239630-A risk allele displayed 1.9-fold higher lumines-
cence (T-test P= 0.0014, Fig. 2b). The same effect was
seen in additional ALL cell lines (Supplementary Fig.2).
rs2239633 and rs2239632 have been reported to affect
CEBPE promoter activity in non B-cell lines [40], however
no relationship was shown in ALL cell lines (Supplemen-
tary Fig.2).
rs2239630 alleles differentially bind SPI1 and MAX
To examine SPI1, MAX, ELF1, YY1, and TCF3 binding at
rs2239630 we performed ChIP in REH and NALM6. Only
SP1 and MAX bound rs2239630 (Fig. 3a, Supplementary
Fig.3A and Supplementary Fig.4). Both REH and NALM6
are heterozygous for rs2239630, allowing allele-speciﬁc q-
PCR to assess allelic bias of binding. MAX and SPI1
demonstrated greater afﬁnity for rs2230630-G non-risk
allele in REH (T-test P= 0.040 and P= 0.038, Fig. 3b) and
NALM6 (T-test P= 0.074 and P= 0.074 Supplementary
Fig.3B).
SPI1 regulates CEBPE expression
We investigated whether differential SPI1 or MAX binding
at rs2239630 accounts for eQTL and luciferase assays by
performing siRNA knockdowns. Reduced MAX expression
had no impact on CEBPE. Conversely, SPI1 depletion
resulted in decreased CEBPE (Fig. 4a, b), a ﬁnding incon-
sistent with rs2239630-A increasing CEBPE expression.
ZNF148 binds the risk allele of rs2239630 and
inhibits expression of CEBPE
To search for additional allele-speciﬁc protein binding at
rs2239630 we performed electrophoretic mobility shift assays
(EMSA). Greater protein or complex binding was shown for
the rs2239630-A allele in REH, SEM, and JURKAT (Fig. 5a
and Supplementary Fig.5). We used HaploReg v4.1 [41],
RegulomeDB [42], and MotifBreakR [43] to identify motifs
Fig. 4 SPI1 but not MAX
regulate CEBPE expression.
a qRT-PCR of SPI1 and MAX
knockdown in REH cells (n=
5). b qRT-PCR of CEBPE
expression in SPI1 and MAX
knockdowns (n= 5). All data
points mean of biological
replicates ± SEM. (T-test P-
values). Target gene expression
normalised to geometric mean of
PPIA and TUBB relative to
negative controls (mock and
non-targeting siRNA) shown on
y-axis
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disrupted by rs2239630 (Fig. 5b). Using the criteria of pre-
ferential afﬁnity for rs2239630-A allele, a predicted strong
effect and expression in REH, identiﬁed ZNF148 and
ZNF589 (Supplementary Table 6). Two mismatches within
the motif of ZNF589 overlapping rs2239630 (Fig. 5b) sug-
gested ZNF148 as the most credible candidate. Performing
EMSA antibody supershift assays with REH nuclear extract
overexpressing ZNF148 identiﬁed ZNF148 as the protein
preferentially bound to rs2239630-A (Fig. 5c). Allele-speciﬁc
binding of ZNF148 was conﬁrmed by ChIP-qPCR (Fig. 6a,
b). To investigate allele-speciﬁc binding of ZNF148 on
CEBPE we generated inducible ZNF148-overexpressing REH
Fig. 5 ZNF148 binds the rs2239630 risk allele. a EMSA allele-speciﬁc
probes for rs2239630 incubated with REH nuclear protein. b Position
weighted matrices for ZNF589 and ZNF148 with corresponding
genomic sequence below. Yellow boxes highlight base mismatches.
c EMSA in REH showing differential allelic binding is caused by
ZNF148. Supershift assay performed by addition of anti-ZNF148
antibody or IgG isotype control
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cells. Overexpression of ZNF148 reduced CEBPE expression
(T-test P= 0.046, Fig. 6c).
rs2239630-A is associated with marks of active
transcription
Since effects of SPI1 and ZNF148 interaction at rs2239630
were inconsistent with higher risk allele CEBPE expression
we sought evidence of allele-speciﬁc expression (ASE). As
it is not possible to directly measure ASE of CEBPE, in the
absence of a proxy coding SNP for rs2239630, we assayed
CEBPE promoter H3K27 acetylation. REH H3K27ac ChIP-
seq showed signiﬁcantly higher reads counts mapping to the
rs2239630-A risk allele (binomial P= 0.027, Fig. 6d), no
bias was present in input DNA (binomial P= 0.99).
Moreover the risk allele bias was higher for rs2239630 than
either rs2239632 or rs2239633. These data are consistent
with increased transcriptional activity due to allele-speciﬁc
promoter acetylation.
Functional and transcriptional proﬁling of CEBPE
To investigate CEBPE function in ALL we generated
doxycycline inducible CEBPE shRNA cell lines, in REH.
CEBPE knockdown reduced cell growth (Fig. 7a), but did
not affect cell cycle or apoptosis (Supplementary Fig.6A).
CEBPE-depleted cells did not show differential apoptosis
either alone or in combination with cisplatin or TNFα
(Supplementary Fig.6B-D).
To identify genes and pathways regulated by CEBPE,
we performed ChIP-Seq and RNA-Seq in CEBPE-
depleted cells. Peak calling of ChIP-Seq data identiﬁed
313 enriched loci, 83 mapping within 1 kb of a
transcription start site (TSS) (Supplementary Table 7).
We identiﬁed enriched motifs using HOMER 4.9.1,
revealing the CEBPE consensus motif as TTGCGCAA
(P= 1 × 10−150) (Supplementary Table 8). Protein-coding
genes showing the highest promoter enrichment were
GAS7, SPRY4, ANKRD13D, TFEB, and ADGB. Pathways
enriched for putative CEBPE-regulated genes were inter-
rogated using REACTOME [44] and PANTHER [45]. Ana-
lyses were consistent with CEBPE binding sites being
enriched in the promoters of genes involved in precursor
metabolites and energy biogenesis (PREACTOME= 5.8 × 10−3,
PPanther= 4.2 × 10−3) and respiration/electron transport
(PREACTOME= 0.01, PPanther= 0.067), which may contribute
to reduced metabolic activity and growth of CEBPE
depleted cells.
Fig. 6 ZNF148 binds the
rs2239630 risk allele and
represses CEBPE. a ZNF148
ChIP q-PCR in REH cells. Left
x-axis raw signal normalised to
input DNA, right y-axis, fold
enrichment (hashed bars) vs IgG
control. b Allele-speciﬁc ChIP
q-PCR for ZNF148 in REH. c q-
RT PCR for ZNF148 and
CEBPE mRNA expression in
ZNF148-overexpressing REH.
T-test P-values. Target gene
expression normalised to
geometric mean of PPIA and
TUBB, shown relative to empty
vector control. Data points,
mean of biological replicates ±
SEM. (d) H3K27ac ChIP-seq in
REH. Reads mapping to each
allele lead SNPs in the 14q11.2
risk loci are enumerated on the
y-axis, hashed bars show the
enrichment for reads mapping to
risk alleles. * binomial P-values
<0.05
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We identiﬁed genes regulated by CEBPE by performing
RNA-Seq in CEBPE-depleted cells (Supplementary
Table 9). Consistent with a role in granulocyte develop-
ment, CEBPE positively regulated MPO and PLD1, genes
of B-cell relevance included IL7R, PRAME, BCL2, and
RASSF4, each positively regulated. To identify differen-
tially expressed genes directly regulated by CEBPE we
mapped ChIP-Seq peaks and gene TSS using Hi-C data in
lymphoblastoid and embryonic stem cells [46]. Findings
were consistent with direct regulation for 13 of 73 top
differentially expressed genes. Hi-C contacts between ChIP-
Seq peaks and TSS were seen for 10 of 73 genes, including
BCL2, MPO, and FAM69C (Supplementary Table 9). The
resolution of Hi-C and proximity of UGT3A2 and CDH12
TSS with ChIP-Seq peaks precluded demonstration of an
interaction. Finally, the promoter of C4orf32 bound CEBPE
directly.
To evaluate the similarity of CEBPE-regulated genes in
CEBPE-depleted and BCP-ALL blast cells we examined
RNA-Seq from 117 diagnostic cases from TARGET [47].
Fig. 7 CEBPE depletion reduces cell growth. Genomic breakpoints in
two IGH-CEBPE ALL cases. a Cell viability/growth assay in CEBPE-
depleted cells. Absorbance (562 nm) normalised to 0 h matched
shRNA control shown on y-axis. * T-test P-value <0.05. Data points,
mean of four biological replicates ± SEM. b Schematic of IGH-
CEBPE translocation breakpoints. Upper panel, RNA and Sanger
sequencing reads spanning ~83Mb between breakpoints, denoted by
dashed lines. Case-speciﬁc breakpoints are denoted by coloured ver-
tical lines. Lower panel, genes mapping to the region and GM12878
H3K27ac ChIP-seq
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First, we identiﬁed CEBPE-correlated genes, restricting our
analysis to those correlated at P < 5 × 10−4, a signiﬁcant
enrichment in differentially expressed genes from CEBPE-
depleted cells was seen (binomial P= 5.4 × 10−4). We next
examined the similarity of CEBPE-correlated gene proﬁles
from two IGH-CEBPE translocated BCP-ALL cases and
117 ALL blasts. CEBPE was highly over-expressed in IGH-
CEBPE translocated cases (mean Z-score= 4.6) and the top
150 differentially expressed genes were highly enriched for
CEBPE-correlated genes in the 117 BCP-ALL cases
(Binomial P= 2.9 × 10−7).
Mapping IGH-CEBPE breakpoints
To explore the integrity of the CEBPE transcript associated
with t(14:14) IGH-CEBPE ALL, we mapped chr14 break-
points by RNA and Sanger sequencing of genomic DNA. In
contrast to the breakpoints in one previously reported IGH-
CEBPE case [13] we observed breakpoints in the 3′ of
CEBPE and the 5′ of IGHJ transcripts in both cases (Fig. 7b
and Supplementary Figure 7 and 8). Although in one case
breakpoints truncated the terminal 13 amino acids of
CEBPE this affected a region of no known function sug-
gesting no functional impact, and in a second case the
coding sequence was unaffected.
The locus upstream of IGHJ breakpoints contains
extensive H3K27ac, associated with enhancer activity,
consistent with this region driving increased CEBPE
expression (Fig. 7). The position breakpoints at IGHJ
implicate aberrant RAG1 and/or RAG2 somatic VDJ
recombination in their formation [48]. However, examina-
tion downstream of CEBPE breakpoints revealed only
consensus RAG hexamer sequence, and not the nonamer
sequence required for canonical RAG activity.
Discussion
Our data provide a plausible mechanism of increased ALL
risk at 14q11.2, driven by increased CEBPE expression
mediated via the rs2239630-A risk allele. Epigenetic, eQTL
and luciferase data suggest differential promoter activity
conferred by rs2239630 results in allele-speciﬁc expression
of CEBPE.
We identiﬁed allele-speciﬁc interaction of SPI1 and
ZNF148 at rs2239630. The regulatory impact of which is to
attenuate increased CEBPE expression associated with
rs2239630-A. This suggests that modulation of expression
due to allele-speciﬁc binding of transcription factors is
complex and the aggregate of multiple interacting proteins.
Previously, Wiemels et al. [49] proposed rs2239635 as
the 14q11 functional variant for ALL. rs2239635, is weakly
correlated with rs2239630 (r2= 0.52) mapping to the 5′-
UTR of CEBPE (Supplementary Figure 9). In contrast to
rs2239630, neither GTEx v7, Blood [39] nor MuTHER [38]
datasets showed a relationship between rs2239635 genotype
and CEBPE expression and RNA-Seq data in chr14 disomic
ALL blasts heterozygous for rs2239635 showed no allele
bias (P= 0.92, n= 20). The authors proposed IKZF1
binding at rs2239635 based on low ChIP enrichment (<2-
fold) in bone marrow, which contains a low proportion of
B-cell lineages. An analysis of eight B-cell ChIP-Seq
datasets in ﬁve B-cell types, including precursors, showed
no evidence of IKZF1 binding rs2239635 [50–53]. Addi-
tionally in silico data, cited by the authors, predicts only a
minimal impact of rs2239635 on IKZF1 binding despite
apparent abolition of risk allele occupancy (Supplementary
Table 10). Furthermore, data from ENCODE suggest
rs2239635 is unbound by transcription factors and pos-
sesses reduced marks of active transcription relative to
rs2239630.
CEBPE is a member of the CEBP transcription factor
family primarily expressed during granulocyte differentia-
tion. Homozygous mutations in CEBPE cause congenital-
speciﬁc granule deﬁciency [54] and mice with CEBPE
disruption have myelopoietic defects [55]. However BCP-
ALL featuring IGH translocations involving CEBP genes
establishes their role in B-cell oncogenesis [13].
We have shown CEBPE depletion reduces growth in
ALL cells. Transcriptional proﬁling of CEBPE-depleted
cells demonstrates that it regulates the expression of genes
with a role in B-cell development (IL7R [56]), apoptosis
inhibition (BCL2 [57]), methotrexate resistance (RASSF4
[58]) and cell survival (PRAME [59]), identifying potential
mediators of disease development.
IL7 signalling is required for adult bone marrow B-cell
production, where it increases B-cell differentiation, pro-
liferation, and survival [60]. Correspondingly, IL7R−/−
mice do not respond to IL7 and have severely reduced B-
and T-cell counts [61]; whereas, transgenic IL7-
overexpressing mice develop lymphoproliferative dis-
orders of B- and T-cell compartments [62].
BCL2 (B-cell lymphoma 2) expression is elevated in
many tumours, including ALL [63, 64], and has been
associated with an adverse prognosis. Correspondingly,
BCL2 inhibition induces apoptosis in a number of ALL cell
lines [57], but not REH, this response has been associated
with serine 70 phosphorylation of BCL2 [65], a mark
lacking in these cells [66]. BCL2 is currently under inves-
tigation as a target for therapy [67].
PRAME (preferentially expressed antigen in melanoma)
expression is elevated in ALL [68] and other malignancies
[59]. PRAME antagonises retinoic acid signalling promot-
ing cell survival [69]. It encodes an antigen recognised by
autologous cytolytic T lymphocytes and has been suggested
as a target for immunotherapy.
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Inherited variation and expression of RASSF4 are asso-
ciated with accumulation of methotrexate polyglutamates
[58]. Methotrexate is one of the main components of ALL
treatment and conversion of the pro-drug to a poly-
glutamated form is required for efﬁcacy.
Taken together this suggests CEBPE inﬂuences the
expression of genes potentially contributing to various
stages of disease development and progression.
Comparing the expression proﬁles of CEBPE-depleted
cells to BCP-ALL blasts we ﬁnd CEBPE expression affects
similar transcriptional programs in both. We also compare
CEBPE-regulated genes in two cases with IGH-CEBPE
translocation with BCP-ALL blasts, again demonstrating
signiﬁcant similarities suggesting that the mechanism by
which CEBPE drives leukemogenesis is the same for
14q11.2 associated and translocated ALL.
In conclusion, we have shown increased CEBPE
expression in ALL patients carrying the rs2239630-A risk
allele, and identiﬁed genes, involved in B-cell development
and apoptosis, via which CEBPE may inﬂuence the risk of
disease, thus providing a mechanistic basis for the 14q11.2
risk association for ALL. Further functional studies, how-
ever, are required to fully decipher the biological basis of
differential CEPBE expression on ALL oncogenesis.
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